GlassScriptPhysician profile
Edward J Oconnor
NPI 1568466555
$26,106.33
in general payments reported to CMS, 2019-2025
64 companies · $4,148 in 2025
The $4,148 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,742 · 2020: $2,832 · 2021: $4,002 · 2022: $3,893 · 2023: $4,020 · 2024: $3,470 · 2025: $4,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,470.28 |
| Education | $167.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,319.70 | 2021-2025 | |
| Ucb, INC. | $1,683.48 | 2019-2025 | Zilbrysq, Rystiggo, Briviact |
| Novartis Pharmaceuticals Corporation | $1,508.99 | 2019-2025 | |
| Lundbeck LLC | $1,504.52 | 2019-2025 | Rexulti, Vyepti |
| Amgen INC. | $1,054.57 | 2019-2025 | Uplizna |
| Lilly USA, LLC | $1,035.28 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Amneal Pharmaceuticals LLC | $1,030.90 | 2019-2025 | Crexont, Rytary |
| Teva Pharmaceuticals USA, INC. | $998.85 | 2019-2024 | Austedo Xr, Austedo |
| Merz Pharmaceuticals, LLC | $997.23 | 2021-2025 | Xeomin, Inbrija |
| Csl Behring | $949.05 | 2019-2025 | Hizentra |
| Biogen, INC. | $868.43 | 2020-2025 | Leqembi, Vumerity, Tysabri |
| Mdd US Operations, LLC | $811.25 | 2019-2025 | Gocovri, Apokyn |
| Kyowa Kirin, INC. | $733.14 | 2019-2024 | Nourianz |
| Upsher-Smith Laboratories LLC | $682.74 | 2019-2022 | |
| Pfizer INC. | $621.58 | 2023-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Oconnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.